Search Results
Mar 17, 2026, 08:36 ET Lo stabilimento di Grangemouth, nel Regno Unito, di Piramal Pharma Solutions consegna con successo il 1500° lotto di ADC
produzione di ADC. In qualità di prima CDMO specializzata in ADC, approvata dalla FDA e prima CDMO a produrre un ADC in ambito commerciale, Piramal dimostra una competenza senza pari in questo settore.Piramal sfrutta tale competenza per fornire una gamma completa di soluzioni integrate per gli ADC dallo
More news about: Piramal Pharma Solutions
Mar 17, 2026, 08:33 ET Abzena Recognized as a Market-Leading Antibody-Drug Conjugate CDMO in Frost & Sullivan Radar Report
& Sullivan applied rigorous criteria to identify the 16 companies featured in the report, including GMP-compliant ADC bioconjugation infrastructure, a proven track record in ADC manufacturing, end-to-end capability, and commercial viability demonstrated by support for multiple clinical-stage programs
More news about: Abzena
Mar 16, 2026, 22:07 ET Werk von Piramal Pharma Solutions im schottischen Grangemouth liefert erfolgreich die 1.500ste ADC-Charge aus
Antikörper-Wirkstoff-Konjugats (Antibody-drug conjugate, ADC) in seiner speziellen Entwicklungs- und Produktionsanlage für Biokonjugate in Grangemouth, Großbritannien, bekannt zu geben. Mit der 1500sten Charge, einer kommerziellen Onkologie-ADC-Charge, unterstreicht dieser Meilenstein die bahnbrechenden Fähigkeiten
More news about: Piramal Pharma Solutions
Mar 16, 2026, 22:05 ET L'usine de Piramal Pharma Solutions à Grangemouth, au Royaume-Uni, livre avec succès le 1 500ᵉ lot d'ADC
CDMO d'ADC approuvé par la FDA et premier CDMO à fabriquer un ADC à des fins commerciales, Piramal fait preuve d'une compétence inégalée dans ce segment.Piramal s'appuie sur cette expertise pour fournir une gamme complète de solutions ADC intégrées à partir de Grangemouth, allant des études de validation
More news about: Piramal Pharma Solutions
Mar 16, 2026, 09:29 ET La planta de Piramal Pharma Solutions en Grangemouth, Reino Unido, entrega con éxito el lote 1.500 de ADC
conjugados anticuerpo-fármaco (ADC). Como la primera CDMO de ADC aprobada por la FDA y la primera CDMO en fabricar comercialmente un ADC, Piramal demuestra una competencia inigualable en este sector. Piramal aprovecha esta experiencia para ofrecer una gama completa de soluciones ADC integradas desde Grangemouth,
More news about: Piramal Pharma Solutions
Mar 16, 2026, 05:31 ET Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
global leader in ADC development and manufacturing. As the first FDA-approved ADC CDMO and the first CDMO to commercially manufacture an ADC, Piramal demonstrates unmatched proficiency in this segment.Piramal leverages this expertise to provide a comprehensive range of integrated ADC solutions from
More news about: Piramal Pharma Solutions
Mar 16, 2026, 05:27 ET Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
global leader in ADC development and manufacturing. As the first FDA-approved ADC CDMO and the first CDMO to commercially manufacture an ADC, Piramal demonstrates unmatched proficiency in this segment.Piramal leverages this expertise to provide a comprehensive range of integrated ADC solutions from
More news about: Piramal Pharma Solutions
Mar 13, 2026, 09:00 ET BioDlink Named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence Awards
BioDlink has been named "Emerging CDMO of the Year" for its innovation in complex biologics and ADC development.The award recognizes its proprietary technology platforms, scalable manufacturing, and a proven quality system with over 100 audits completed.
More news about: BioDlink Biopharm Co., Ltd.
Mar 13, 2026, 08:00 ET Kestrel Group Reports Fourth Quarter and Full Year 2025 Financial Results
largely offset by an increase of $4.2 million in the amount recoverable under the Loss Portfolio Transfer and Adverse Development Cover Agreement ("LPT/ADC Agreement") with Cavello Bay Reinsurance Limited. AmTrust's Hospital Liability business experienced modestly favorable development of approximately
More news about: Kestrel Group Ltd
Mar 12, 2026, 23:09 ET WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
Asia-Pacific Biopharma Excellence Awards honor outstanding innovation, operational rigor, and industry leadership across bioprocessing, supply chain, ADC development, and clinical development. Recognizing the remarkable contributions of leading biopharma professionals, organizations, and technologies,
More news about: WuXi Biologics
Mar 12, 2026, 08:15 ET PhotonIC Launches the PHPM1108 Multi-Channel IDAC with Industry-Leading High-Current, Low-Noise, and Low-Power for External Laser Sources used in AI Optical Modules
(per Channel) or 4A (8 Channels Combined) High-accuracy 12-bit Programmable Constant Current Output 11-bit SAR ADC for laser voltage and temperature monitor Supports Max 1MHz I2C CLK Full Protection with On-Chip Fault Detection (Bypassable
More news about: PhotonIC Technologies
Mar 12, 2026, 08:00 ET Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
Actively recruiting Phase 1 trials for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 and MUC16-targeted ADC HWK-016HWK-206 on track for planned IND submission in mid-2026 and Phase 1 start in Q3Cash, cash equivalents
More news about: Whitehawk Therapeutics, Inc.
Mar 12, 2026, 05:00 ET Earendil Labs and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Bispecific/Multispecific Antibodies and ADCs
the signing of a strategic collaboration agreement on the development and manufacturing of multiple novel bispecific and multispecific antibodies and ADC candidates in Earendil Labs' pipeline targeting autoimmune disease, cancer, and other diseases. Under the agreement,
More news about: Earendil Labs
Mar 10, 2026, 17:31 ET CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
the disease, historical and forecasted epidemiology, market share of the individual therapies, and key non-hodgkin's lymphoma companies, including ADC Therapeutics, Bristol-Myers Squibb, Roche, Amgen, Johnson & Johnson, Celgene Corp., Mesoblast, Genmab, Novartis, Teva Pharmaceutical Industries,
More news about: DelveInsight Business Research, LLP
Mar 10, 2026, 11:30 ET Jacobio Announces 2025 Annual Results
First Commercial Product Glecirasib Approved and Added to China's NRDLpan-KRAS and Innovative ADC Pipeline Continue to AdvanceBEIJING, SHANGHAI and BOSTON, March 10, 2026
More news about: Jacobio Pharma
Mar 10, 2026, 07:30 ET ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
call.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Mar 09, 2026, 17:31 ET Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight
monoclonal antibody linked via a cleavable connector to a novel camptothecin-based topoisomerase I inhibitor. This agent was engineered using the TMALIN ADC platform, designed to exploit the tumor microenvironment and address limitations seen in earlier-generation ADCs. Zai Lab initiated a Phase I/II trial
More news about: DelveInsight Business Research, LLP
Mar 09, 2026, 06:47 ET Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
Mar 09, 2026, 06:00 ET IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
IDEAYA may evaluate additional combinations between IDE397 and other TOP1 payload ADCs in this setting, including IDE034, its B7H3/PTK7 bispecific TOP1 ADC. MTAP deletion is estimated to occur in 15–20% of non-small cell lung cancer, up to 40% of pancreatic cancer, and approximately 15% of all solid
More news about: IDEAYA Biosciences, Inc.
Mar 09, 2026, 04:32 ET Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Harbour BioMed
Mar 09, 2026, 02:28 ET Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer
proprietary technology platforms, including LeadsBody platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform), TOPiKinectics (ADC platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of our bispecific antibody portfolios.We
More news about: Leads Biolabs
Mar 05, 2026, 08:00 ET AI Accelerates API Sprawl: Application Security and Delivery Up 15 percent in 2025, According to Dell'Oro Group
consistent enforcement for rapidly changing application surfaces, with suite packaging and shared policy models emerging as key differentiators.ADC: Demand continued to shift toward software-centric delivery models that support portability, automation, and modern application architectures, with
More news about: Dell'Oro Group
Mar 04, 2026, 21:26 ET Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results
Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and
More news about: Akeso, Inc.
Mar 04, 2026, 08:52 ET Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and
More news about: Akeso, Inc.
Mar 04, 2026, 08:05 ET INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and
More news about: INOVIO Pharmaceuticals, Inc.